UAE-based Mubadala Bio has partnered with Argentine biopharmaceutical company Biosidus to improve regional access to biologic therapies, reinforcing the UAE’s strategy to strengthen healthcare manufacturing, biotechnology innovation and pharmaceutical self-sufficiency.
The partnership will focus on expanding the availability of advanced biologic medicines while supporting localized production capabilities and strengthening the life sciences ecosystem across the Middle East.
The agreement reflects the UAE’s broader ambition to position itself as a regional hub for pharmaceutical manufacturing, biotechnology research and healthcare innovation.
Biologics Become a Strategic Healthcare Priority
Biologic therapies are among the fastest-growing segments of the global pharmaceutical industry, offering advanced treatments for conditions including cancer, autoimmune disorders, diabetes and rare diseases.
Unlike conventional medicines, biologics are produced using living organisms and require sophisticated manufacturing capabilities, stringent quality controls and specialized research expertise.
Expanding regional production can improve supply chain resilience, reduce dependence on imported medicines and improve patient access to advanced therapies.
The collaboration between Mubadala Bio and Biosidus reflects increasing investment in high-value biopharmaceutical manufacturing across the Gulf.
Strengthening Regional Pharmaceutical Manufacturing
Governments across the Middle East are investing in domestic pharmaceutical production as part of broader healthcare resilience strategies.
Local manufacturing capabilities help improve medicine availability, strengthen supply chain security and reduce exposure to global disruptions.
For the UAE, partnerships with international biotechnology companies support knowledge transfer, advanced manufacturing capabilities and workforce development while accelerating the growth of the national life sciences sector.
The initiative aligns with wider efforts to build a diversified, innovation-led healthcare economy.
Biotechnology Supports Economic Diversification
Biotechnology is emerging as a strategic growth sector that combines healthcare innovation with advanced manufacturing and scientific research.
Investments in biologics production contribute not only to improved healthcare outcomes but also to economic diversification by creating high-skilled jobs and attracting research and development activities.
The UAE has been expanding investments in biotechnology, genomics, precision medicine and pharmaceutical manufacturing as part of its long-term industrial strategy.
International collaborations are helping accelerate these ambitions through technology transfer and commercial partnerships.
Building a More Resilient Healthcare Ecosystem
The COVID-19 pandemic underscored the importance of strengthening domestic healthcare capabilities and securing access to essential medicines.
Today, many countries are investing in localized production of pharmaceuticals, vaccines and biologics to improve long-term healthcare resilience.
Partnerships such as Mubadala Bio and Biosidus demonstrate how collaboration between regional and international organizations can expand manufacturing capacity while improving access to advanced treatments.
Industry analysts expect continued investment in biotechnology infrastructure as demand for biologic medicines continues to grow globally.
Why This Matters
Biologic therapies represent one of the most advanced areas of modern medicine, but access remains constrained in many markets due to manufacturing complexity and supply chain limitations. Expanding regional production helps improve healthcare resilience while increasing patient access to innovative treatments.
For the UAE, the partnership strengthens national ambitions to become a regional biotechnology and pharmaceutical manufacturing hub. For the healthcare sector, it highlights the growing importance of localized life sciences capabilities in supporting both public health and long-term economic diversification.
Editor’s Note
Healthcare is becoming an increasingly strategic component of national industrial policy. Countries are no longer focused solely on importing advanced medicines but are investing in the capabilities to develop and manufacture them locally. The partnership between Mubadala Bio and Biosidus reflects this shift, positioning biotechnology alongside AI, semiconductors and advanced manufacturing as a pillar of knowledge-based economic growth. As demand for biologic therapies continues to rise worldwide, regions that build strong biopharmaceutical ecosystems will be better positioned to improve healthcare outcomes while strengthening economic resilience.
